Artesunate for injection (Amivas LLC), a semi-synthetic artemisinin derivative, is now approved by the FDA for initial (induction) treatment of severe malaria in children and adults. It has been available from the CDC on a compassionate use basis since 2007.1 Artemether/lumefantrine (Coartem), another artemisinin-based drug, was approved earlier for oral treatment of uncomplicated Plasmodium falciparum malaria.2 IV artesunate is now the only FDA-approved injectable antimalarial drug available in the US; IV quinidine has been discontinued.
SEVERE MALARIA — Complications of severe malaria, which...
- Lumateperone (Caplyta) for Schizophrenia
- Durysta - A Bimatoprost Implant for Glaucoma
- Drugs Past Their Expiration Date
- Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy
RELEASE
The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for on-demand contraception; it is not effective when used after intercourse. It was previously approved for use as a vaginal lubricant (Amphora), but was never marketed.
RELEASE
A transdermal formulation of the second-generation (atypical) antipsychotic asenapine (Secuado – Noven) has been approved by the FDA for once-daily treatment of schizophrenia in adults. Asenapine is the first antipsychotic to become available in a transdermal formulation in the US. A twice-daily sublingual tablet formulation of asenapine (Saphris) has been available since ...
